Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Zinner

Showing results (71-80 of 104) with videos related to

Pageof 11
Sort By:
The Oncologist|February 23, 2011
Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinicFilip Janku, Apostolia M Tsimberidou, Xuemei Wang, et al.
American Journal of Clinical Oncology|August 19, 2009
Phase II study of vinorelbine and docetaxel in the treatment of advanced non-small-cell lung cancer as frontline and second-line therapyWilliam N William, Fadlo R Khuri, Frank V Fossella, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2007
Phase I clinical and pharmacodynamic evaluation of oral CI-1033 in patients with refractory cancerRalph G Zinner, John Nemunaitis, Irene Eiseman, et al.
Molecular Cancer Therapeutics|August 22, 2013
Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutationsJennifer J Wheler, Apostolia M Tsimberidou, Gerald S Falchook, et al.
Investigational New Drugs|January 23, 2010
Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC)Hai T Tran, Ralph G Zinner, George R Blumenschein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2005
Phase 1 clinical and pharmacokinetics evaluation of oral CI-1033 in patients with refractory cancerJohn Nemunaitis, Irene Eiseman, Casey Cunningham, et al.
International Journal of Radiation Oncology, Biology, Physics|June 17, 2008
Dose escalation of gemcitabine is possible with concurrent chest three-dimensional rather than two-dimensional radiotherapy: a phase I trial in patients with stage III non-small-cell lung cancerRalph G Zinner, Ritsuko Komaki, James D Cox, et al.
Nature Biotechnology|December 24, 2002
Fingerprinting the circulating repertoire of antibodies from cancer patientsPaul J Mintz, Jeri Kim, Kim-Anh Do, et al.
Cancer|April 23, 2014
A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701)Gerold Bepler, Ralph G Zinner, James Moon, et al.
Oncogene|October 10, 2020
S6K1 blockade overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancerHua Shen, Gao-Chan Wang, Xiang Li, et al.
Pageof 11

Showing results (71-80 of 104) with videos related to

Sort By:
Pageof 11
The Oncologist|February 23, 2011
Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinicFilip Janku, Apostolia M Tsimberidou, Xuemei Wang, et al.
American Journal of Clinical Oncology|August 19, 2009
Phase II study of vinorelbine and docetaxel in the treatment of advanced non-small-cell lung cancer as frontline and second-line therapyWilliam N William, Fadlo R Khuri, Frank V Fossella, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2007
Phase I clinical and pharmacodynamic evaluation of oral CI-1033 in patients with refractory cancerRalph G Zinner, John Nemunaitis, Irene Eiseman, et al.
Molecular Cancer Therapeutics|August 22, 2013
Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutationsJennifer J Wheler, Apostolia M Tsimberidou, Gerald S Falchook, et al.
Investigational New Drugs|January 23, 2010
Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC)Hai T Tran, Ralph G Zinner, George R Blumenschein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2005
Phase 1 clinical and pharmacokinetics evaluation of oral CI-1033 in patients with refractory cancerJohn Nemunaitis, Irene Eiseman, Casey Cunningham, et al.
International Journal of Radiation Oncology, Biology, Physics|June 17, 2008
Dose escalation of gemcitabine is possible with concurrent chest three-dimensional rather than two-dimensional radiotherapy: a phase I trial in patients with stage III non-small-cell lung cancerRalph G Zinner, Ritsuko Komaki, James D Cox, et al.
Nature Biotechnology|December 24, 2002
Fingerprinting the circulating repertoire of antibodies from cancer patientsPaul J Mintz, Jeri Kim, Kim-Anh Do, et al.
Cancer|April 23, 2014
A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701)Gerold Bepler, Ralph G Zinner, James Moon, et al.
Oncogene|October 10, 2020
S6K1 blockade overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancerHua Shen, Gao-Chan Wang, Xiang Li, et al.
Pageof 11